MX2025001384A - Forma cristalina de derivado triciclico fusionado y metodo de preparacion - Google Patents
Forma cristalina de derivado triciclico fusionado y metodo de preparacionInfo
- Publication number
- MX2025001384A MX2025001384A MX2025001384A MX2025001384A MX2025001384A MX 2025001384 A MX2025001384 A MX 2025001384A MX 2025001384 A MX2025001384 A MX 2025001384A MX 2025001384 A MX2025001384 A MX 2025001384A MX 2025001384 A MX2025001384 A MX 2025001384A
- Authority
- MX
- Mexico
- Prior art keywords
- crystal form
- preparation
- fused tricyclic
- tricyclic derivative
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente descripción se refiere a una forma cristalina de un derivado tricíclico fusionado y a un método de preparación, y se refiere específicamente a una forma cristalina de un 5 compuesto (3S,4R)-4-((5-cloro-4-((S)-8-fluoro-2-(2-hidroxipropano-2-il)-3-metil-3,4-dihidro-5-oxa-1,2a-diazacenaftileno-6-il)pirimidina-2-il)amino)tetrahidro-2H-piran-3-ol, una sal farmacéuticamente aceptable del mismo, y a un método de preparación correspondiente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210915848 | 2022-08-01 | ||
| PCT/CN2023/110180 WO2024027631A1 (zh) | 2022-08-01 | 2023-07-31 | 一种稠三环类衍生物的晶型及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025001384A true MX2025001384A (es) | 2025-03-07 |
Family
ID=89848540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025001384A MX2025001384A (es) | 2022-08-01 | 2025-01-31 | Forma cristalina de derivado triciclico fusionado y metodo de preparacion |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4567040A4 (es) |
| JP (1) | JP2025528074A (es) |
| KR (1) | KR20250040728A (es) |
| CN (1) | CN119522226B (es) |
| AU (1) | AU2023319371B2 (es) |
| MX (1) | MX2025001384A (es) |
| TW (1) | TW202406912A (es) |
| WO (1) | WO2024027631A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121399137A (zh) * | 2023-07-27 | 2026-01-23 | 上海拓界生物医药科技有限公司 | 一种含氧稠三环衍生物及其制备方法和用途 |
| WO2026158568A1 (zh) * | 2025-01-24 | 2026-07-30 | 江苏恒瑞医药股份有限公司 | 一种细胞周期蛋白依赖性激酶抑制剂的结晶形式、药物组合物及用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110818690B (zh) * | 2016-07-26 | 2021-08-10 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| KR102543603B1 (ko) * | 2016-12-22 | 2023-06-14 | 베타 파머수티컬 컴퍼니 리미티드 | 벤조이미다졸 유도체, 제조 방법 및 그것의 용도 |
| CN118286225A (zh) * | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| CN113698391B (zh) * | 2020-05-21 | 2023-06-06 | 上海拓界生物医药科技有限公司 | 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法 |
| CN120682245A (zh) * | 2021-02-03 | 2025-09-23 | 江苏恒瑞医药股份有限公司 | 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途 |
| CN117486898A (zh) * | 2022-08-01 | 2024-02-02 | 江苏恒瑞医药股份有限公司 | 一种稠三环类衍生物的晶型及制备方法 |
-
2023
- 2023-07-31 WO PCT/CN2023/110180 patent/WO2024027631A1/zh not_active Ceased
- 2023-07-31 JP JP2025505841A patent/JP2025528074A/ja active Pending
- 2023-07-31 EP EP23849339.9A patent/EP4567040A4/en active Pending
- 2023-07-31 AU AU2023319371A patent/AU2023319371B2/en active Active
- 2023-07-31 TW TW112128660A patent/TW202406912A/zh unknown
- 2023-07-31 CN CN202380054075.5A patent/CN119522226B/zh active Active
- 2023-07-31 KR KR1020257006346A patent/KR20250040728A/ko active Pending
-
2025
- 2025-01-31 MX MX2025001384A patent/MX2025001384A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023319371A1 (en) | 2025-03-06 |
| JP2025528074A (ja) | 2025-08-26 |
| EP4567040A4 (en) | 2025-11-12 |
| AU2023319371B2 (en) | 2026-07-16 |
| CN119522226B (zh) | 2026-08-11 |
| EP4567040A1 (en) | 2025-06-11 |
| CN119522226A (zh) | 2025-02-25 |
| WO2024027631A1 (zh) | 2024-02-08 |
| TW202406912A (zh) | 2024-02-16 |
| KR20250040728A (ko) | 2025-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599342A (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
| WO2007023382A3 (en) | Pyrimidine amino pyrazole compounds, potent kinase inhibitors | |
| MXPA04003759A (es) | Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv. | |
| WO2006106423A3 (en) | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase | |
| EA201891463A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK) | |
| NZ578876A (en) | 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors | |
| AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| TW200612936A (en) | Indole derivatives | |
| TW200736258A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| MX2023006842A (es) | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. | |
| WO2009018065A3 (en) | Novel glucokinase activators and methods of using same | |
| WO2005070884A3 (en) | Heterocyclic compounds useful as growth hormone secretagogues | |
| PH12021552533A1 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| MY169232A (en) | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same | |
| MX2023004102A (es) | Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. | |
| ZA202500857B (en) | Compounds and methods for modulating her2 | |
| MX2025005861A (es) | Sal farmaceuticamente aceptable de compuesto heterociclico que contiene nitrogeno, forma cristalina de la misma y metodo de fabricacion de la misma | |
| IL277904B2 (en) | History of indan for use in the treatment of pain and inflammation | |
| WO2021226276A3 (en) | Nampt modulators | |
| WO2007083188A3 (en) | Improved process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative | |
| TW200626158A (en) | Naphthaline derivatives | |
| MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
| WO2018127526A3 (en) | Solid forms of [(1 s)-1 -[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate | |
| WO2006030211A3 (en) | Acyclic sulphonamides |